ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
This is a study of dose dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel (Taxol; T) with pegfilgrastim (Neulasta) and darbepoetin alfa support in the adjuvant breast cancer setting.
Breast Cancer
DRUG: Neulasta|DRUG: Aranesp
The proportion of subjects experiencing any delay in any cycle of chemotherapy over the course of the study, 3 months
Febrile neutropenic events and adverse event profile will be assessed, 4 months|To assess chemotherapy and subject dose delays and reductions which are specific and/or non specific to haematological toxicities, 3 months|Frequency of red blood cell (RBC) transfusions, 3 months
This is a study of dose dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel (Taxol; T) with pegfilgrastim (Neulasta) and darbepoetin alfa support in the adjuvant breast cancer setting.